Corporate Presentation October New growth cycle and value innovation

Similar documents
Corporate Presentation 1Q18. New growth cycle and value innovation

Enel Américas 1Q 2018 results

Grupo Fleury announces the acquisition of Grupo Papaiz, entering the dental diagnostics market. September 28th, 2012

Telekom Austria Group Results for the 1st Quarter May 27, 2003

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

MARCH 2014 RESULTS PRESENTATION Madrid, 2014

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Prodent Introduction. Welcome

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

For personal use only

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

Growth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008

The Dental Corporation Opportunity

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

Genomic Health. Kim Popovits, Chairman, CEO and President

Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

Myriad Genetics Corporate Presentation 06/13/2018

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

January 30, 2018 Dow Wilson President and Chief Executive Officer

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

Investor Presentation

HILLENBRAND INDUSTRIES INC

BALCHEM CORPORATION. Q Investor Relations Presentation

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010

Forward Looking Information

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

LED Medical Diagnostics Inc. TSXV: LMD / OTCQB:LEDIF

Endesa 1Q 2017 Results 09/05/2017

Q Investor Kit JANUARY-MARCH 2014

Zacks Small-Cap Research

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

Q Investor Kit January December 2014

Putting ALK on the right growth trajectory

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Coloplast A/S. Investor presentation 1H 2005/06

Total Face Group Limited

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address

To be the partner of choice Straumann

ASX Investor Presentation

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

Letter to Shareholders SEMI-ANNUAL REPORT 2008

FIRSTQUARTER2018 RESULTSPRESENTATION

Altria Group Inc. Ticker: MO

Q Investor Kit JANUARY-JUNE 2013

Summary of Results for the First Half of FY2015/3

ASX Announcement 22 June 2017

For personal use only

Results Presentation 2Q FY March Win-Partners Co., Ltd. (3183)

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

FY2016 1H Results. Cookpad Inc.

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

QUALITAS MEDICAL GROUP LIMITED. CORPORATE PRESENTATION January 2010

Universal Biosensors, Inc.

artnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Südzucker Group Capital market forum Rhine Neckar

Annual Shareholders Meeting

Investor Presentation

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016

Global Invisible Braces Market: Trends, Opportunities and Forecasts ( )

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

MYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017

A world leader in allergy immunotherapy

Q Investor Kit JANUARY-JUNE 2014

1Q2005. Hera Group presentation

Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile

Designing a Smoke-Free Future

Shareholder Presentation Annual Meeting 2018

Jefferies Healthcare Conference. June 2016

A GLOBAL LEADER IN PERSONALIZED NUTRITION

Operational Efficiency:

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

1Q 2015 Results A Positive Start to 2015

Cowen Healthcare Conference

Insurance Guide For Dental Healthcare Professionals

Cochlear Limited 2018 Annual General Meeting Chairman s Address

Position Profile Chief Executive Officer Feeding America San Diego San Diego, CA

ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.

Telekom Austria Group Results for the First Quarter May 16, 2007

William Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Forward-Looking Statements

For personal use only

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

6.00% CAP Rate $5,600,000. DeerfieldPartners. John Giordani Art Griffith (415) Actual Store

WELCOME TO ACTELION S AGM 2015

Transcription:

Corporate Presentation October 2017 New growth cycle and value innovation

Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Strategic competitive advantages 4 Financial and Operational Performance 5 Capital Markets 2

Dental benefits: an incipient sector in Brazil 3 1

Brazil leads the global ranking of dentists Number of dentists per country (thousand) 290 ¹ 12% of the dentists in the world are located in Brazil 160 63 52 40 37 35 30 29 26 25 22 21 21 18 18 16 12 11 4 Source: FDI World Dental Federation The Oral Health Atlas 2009 ¹ Federal Council of Dentistry Brazil (September 2017)

Brazilian dental opportunity Although 12% of world s dentists are located in the country, only 11% of brazilians have a dental plan 60% 11% % of the population covered by a private dental plan 14 5 Source: OdontoPrev

Great portion of middle class don t have dental plan 100 22 Potential Market of 78 Million people in the middle class Million people already dental plan members million people 6

Proprietary research confirms importance of dentistry Do you believe your smile is your best business card? 76% totally/partially agree 7 Totally disagree Partially disagree Neutral Partially agree Totally agree

Cost per client Cost per client Attractive cost dynamics Over time, OdontoPrev Dental Plans present a predictable Medical Plans OdontoPrev Plans Price Cost Price Cost Time Cost increases by medical inflation and better technology Short-term contract: 1 year tenor TIme Predictable cost evolution due to prevention Long-term contract: 2 year + duration 8 and more attractive cost profile than Medical Plans.

OdontoPrev Prepaid Business Model High predictability of cash flow No working capital needs Low CAPEX requirements Positive cash flow generation every day Customers Fee per user Dental care reimbursement R$ R$ Accredited dentist network 9

Inside OdontoPrev2

OdontoPrev: 10 years of sustainable value creation since IPO Net revenues (R$ million) 1,070 1,156 1,250 1,365 1,402 955 685 835 182 259 318 382 IPO 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 JUL16 JUN17 11

Revenue & membership market share: 2007-2016 Revenue market Share (%) Membership market Share (%) 40.9 42.0 43.0 44.0 43.3 43.2 45.4 28.7 30.0 34.3 33.3 32.3 31.5 31.0 30.2 28.4 25.1 23.1 22.2 20.5¹ 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 12 Source: ANS and OdontoPrev ¹ OdontoPrev membership portfolio ex-bradesco

Individual plans & SME: higher growth and better returns JUL16 - JUN17 AVERAGE TICKET (R$ / member / month) Contribution Margin 37 Individual Plans Revenues JUL16-JUN17 R$273 M (+33% YoY) 53% 20 Corporate SME Revenues JUL16-JUN17 R$202 M (+16% YoY) 43% 17 Revenues JUL16-JUN17 R$918 M (-2% YoY) 38% 13 ¹ M: million High Low NUMBER OF COMPETITORS

Strategic competitive advantages 3

Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 15

Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 16

Proprietary IT Platform: information-driven decisions 17 + Complete dental record of all beneficiaries + 29 years of actuarial data + Risk Management and fraud prevention

Proprietary IT Platform: information-driven decisions + Quality assurance + Clear barrier to entry + Cost control 18

Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 19

Increasing online search for dental plans Number of dental plans search in Brazil (000 / month) 20

Innovation driven Company + OdontoPrev online: individual plans sold at the web + Launched NEW September 1st + Exclusive App for the accredited dentists network 21

Wide range of unique dental care solutions OdontoPrev online Baby tooth Well being Dental Aesthetics Dental Orto Dental VIP 22

From basic cover to aesthetic solutions Fluorine Pediatric dentistry 24/7 emergency Surgery Wisdom tooth extraction Restoration Cleanings Orthodontic radiography Braces Whitening Prosthesis Baby tooth Well being Being Dental Dental aesthetics Dental Orto Dental VIP 23

Innovation driven Company Top quality dental materials delivered door to door to the dentist free of charge Exclusive agreement to prevent oral cancer 24

Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 25

Dental and medical plans evolution Million members Medical plans Dental plans 47.8 49.4 50.4 49.2 47.6 47.3 18.5 19.8 20.7 21.2 21.7 22.7 2012 2013 2014 2015 2016 AUG/17 2012 2013 2014 2015 2016 AUG/17 26 Source: ANS August 2017.

Dental Plans sector evolution Million members 17.7 18.5 19.8 20.7 21.2 21.7 22.7 7.3 9.2 11.1 13.3 14.5 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 AUG17 27 Source: ANS

Focused & dental only leadership since 1998 Key players, brazilian dental sector (AUGUST 2017 thousand members) 6,190¹ 27% market share of beneficiaries² 1,943 1,640 1,571 436 958 842 520 500 28 ¹OdontoPrev 2Q17 ² Source: ANS ( ) ( )

3 accelerated growth cycles, over the last decade, brings new investors to the sector

Cycle 01: Bradesco Dental 2006-2009 (million members) OdontoPrev EBITDA (R$ million and % Sales) Average ticket (R$/member/month) 12.25 12.53 12.07 12.80 76 81 60 46 25.1% 23.3% 23.9% 11.1 13.3 9.2 21.1% 7.3 0.6 1.5 30 2006 2007 2008 2009 Source: ANS 2006 2007 2008 2009 2006 2009

Cycle 02: Amil sold to UnitedHealthcare in 2013 (million members) OdontoPrev EBITDA (R$ million and % Sales) Average ticket (R$/member/month) 12.87 13.66 14.33 15.22 227 208 273 2.1 154 22.4% 24.9% 23.8% 25.5% 1.3 31 2010 2011 2012 2013 Source: ANS 2010 2013

Negative results in Brazil 2014-2016 2014 Net loss (R$ million) 2015 2016-108 -289-318 32 Source: Amil (Valor Econômico)

Cycle 03: Hapvida & Interodonto 2014 JUL17 (million members) OdontoPrev EBITDA (R$ million and % Sales) Average ticket (R$/member/month) 18.58 16.07 17.04 327 305 300 + 19.36 312 1.6 1.6 26.4% 26.2% 22.0% 23.3% 1.0 1.0 2014 2015 2016 JUL16 JUN17 2014 Aug/17 2014 Aug/17 33 Source: ANS

Dental plans sector evolution DEC14 AUG17 Thousand members +622 22,667 20,707 +586 +560 +192 Others DEC14 With 18% of market share, three companies represented 68% of the sector growth since 2014. AUG17 34 Source: ANS

Change in control brings a new strategy of peers Thousand members ( ) 1,878 2,062 1,808 1,846 1,944 1,943 1,571 1,260 1,262 1,023 962 1,011 1,054 ( ) 2011 2012 2013 2014 2015 2016 AUG/17 35 Source: ANS

Cross-selling dental/medical has limited upside Players Dental (A) Medical (B) A / B 1.571 1.959 80% 1.640 2.189 75% 36 Source: ANS August 2017

Average ticket evolution (R$/member/month) 2011-2016 14.3 13.7 11.8 12.1 9.0 9.1 15.2 11.5 9.6 18.6 17.0 16.1 12.5 12.8 12.9 10.1 10.5 N/A 2011 2012 2013 2014 2015 2016 37 Source: ANS

Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 38

Best in class distribution channels Direct selling Bank channels Brokers Online selling Retailers Medical Plan Organizations 39

The largest bancassurance platforms in Brazil Clients + 80 million + 60 million National footprint Exclusivity 20 years 48% of branches & 52% of brazilian bank clients 40

Banks: strong and committed long-term partners + Back-office Price maker Product design Customer relationship Dentist network management Front-office Price takers Selling National footprint capilarity Bank branches and brokers distribution 41

Strategic competitive advantages World Class Dental IT Platform Largest and Specialized Dentist Network Innovation Driven Company Exclusive Distribution Channels 100% Dental Focused 42

Largest and best dentist network 28,000 dentists at 2,200 cities National distribution Differentiated academic background Continuous education 24/7 call center 43

OdontoPrev: 4 Financial and Operational Performance

More positive headlines 45

Net Revenues R$ million 1,402 1,156 1,250 1,365 955 1,070 5.6% 669 706 4.6% 339 354 46 2012 2013 2014 2015 2016 JUL16 6M16 6M17 2Q16 2Q17 JUN17

Revenue growth per segment in 2Q17 R$ million R$ million +20.6% +4.6% 354 59 46 +17.1% 71 53 339 17% 69% 14% 65% 20% 15% 234 227 2Q16 2Q17 2Q16 2Q17 Corporate SME Individual Plans 47

2Q17 Members, revenues and contribution margin Members Revenue Contribution Margin 75% 15% 10% 65% 20% 15% 61% 23% 16% Corporate SME Individual Plans 48

Average Ticket per Segment (R$/member/month and YoY % ) +12.6% 2.1% 18.41 10.7% 20.37 34.02 38.30 16.57 16.92 2Q16 2Q17 2Q16 2Q17 2Q16 2Q17 Corporate SME Individual Plans 49

Breakdown of individual plans Thousand members +4% 632 10% 657 3% 2% 56% 41% 258K members 43% 283K members 55% 2Q16 2Q17 Retailers 50

Positive effects of bank channels 2Q17 List prices & R$45.60 Retailers R$29.90 Selling expenses Profitability 10% - 15% Higher 25% - 45% Lower 51

Breakdown of SME members Thousand members +6% 912 863 1% 83% 16% 79% 7% 14% 718K members 721K members 2Q16 2Q17 52

Quarterly and LTM Cost of Services (% of Sales) 54.6 52.6 51.4 50.0 49.4 49.7 48.8 48.8 48.6 48.7 49.0 48.2 48.2 48.4 47.6 47.6 47.5 47.4 46.6 46.4 46.0 46.1 46.0 45.2 45.0 44.0 43.7 43.9 43.4 2011 2012 2013 2014 2015 2016 2017 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q¹ Quarterly LTM 53 ¹Excludes Bradesco Dental and OdontoPrev INSS reversals

Dental Loss Ratio (% of Sales) per segment 56 61 58 53 54 Corporate 45 50 46 42 43 SME 25 27 26 24 27 Individual Plans 2Q16 3Q16 4Q16 1Q17 2Q17 54

Key metrics per segment (% of Sales) 55.6 53.7 53.0 48.9 44.8 44.9 43.2 40.9 42.4 38.8 24.8 26.8 22.2 24.3 12.8 11.9 5.6 5.4 2Q16 2Q17 2Q16 2Q172Q16 2Q17 2Q16 2Q17 2Q16 2Q17 2Q16 2Q17 2Q16 2Q17 2Q16 2Q17 2Q16 2Q17 Corporate SME Individual Plans Cost of Services Selling expenses Contribution Margin 55

G&A (% of Sales) 15.6 14.7 13.8 14.2 14.4 14.8 14.5 Personnel 7.8 7.9 7.3 7.4 7.7 7.9 8.0 Others 7.7 6.8 6.5 6.8 6.7 6.9 6.5 # of employees 1,525 1,587 1,560 1,588 1,581 1,460 1,509 2011 2012 2013 2014 2015 2016 6M17¹ 56 ¹Excludes Bradesco Dental and OdontoPrev INSS reversals

Allowance for doubtful receivables R$ million and % of Sales 17.5 15.7 16.0 13.9 5.0 4.6 4.6 4.1 11.5 3.2 2Q16 3Q16 4Q16 1Q17 2Q17 R$ million % of Sales 57 57

Adjusted EBITDA and Adjusted EBITDA margin (ex-inss¹) R$ million and % of Sales 273 305 327 300 312 208 24.9 227 23.8 25.5 26.4 26.2 164 24.5 176 25.0 76 86 24.3 22.0 22.3 22.4 2011 2012 2013 2014 2015 2016 JUL16 6M16 6M17¹ 2Q16 2Q17¹ JUN17¹ 58 ¹Excludes Bradesco Dental and OdontoPrev INSS reversals

Net Income (ex-inss¹) R$ million 188 195 221 216 224 145 146 113 121 44 52 2011 2012 2013 2014 2015 2016 JUL16 JUN17¹ 6M16 6M17¹ 2Q16 2Q17¹ 59 ¹Excludes Bradesco Dental and OdontoPrev INSS reversals

Quarterly cash dividends to investors (R$ million) INSS approval brings 100% payout policy from 3Q17 111 11 55 12 43 35 11 24 35 11 24 47 12 35 55 13 43 100 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 Dividends Interest on capital 60

Net cash (R$ million) 515¹ 443¹ 208 218 257 266 334 2011 2012 2013 2014 2015 2016 2Q17 61 ¹ Includes R$114.8 million dedicated to ANS.

Cash Flow since the IPO R$ million +2,068.5 22.6% of sales +329.6-15.0 Share buyback -120.1-98.0-362.5 Capital reductions -1,428.9 Cash dividends 204.7-1,806.4-63.7 514.6 Net Cash DEC06 + - - + - - = Cash Generation Acquisitions Capex Shareholder Remuneration Stock Options² Net Cash JUN17¹ 62 ¹ Includes R$114.8 million dedicated to ANS ² Stock Options Program vesting reimbursement

INSS: Provisions reversals in 2Q17 Until 2010 After 2010 Amount provisioned R$45 million R$303 million Approval July 10th, 2017 July 14th, 2017 Cash effect Yes, in 3Q17 No Annual growth Selic (*) Selic (*) + R$ 45 million 63 * Brazilian interest rate

Key takeaways More positive outlook for new members Loss ratio back to historical levels Tax savings to expand margin From 80% to 100% payout ratio 64

Capital Markets 5

Global shareholder structure: investors from 37 countries 66 Source: OdontoPrev

Corporate Governance and professional management team 67

Superior Corporate Governance Standards Chairman # CEO, since the 1990s Board of Directors without executive functions, 56% independent members AGM previous notice to shareholders of 30 days Disclosure of minimum, average and maximum annual compensation of executives 3 CEOs since the foundation in 1987, and 1 IRO since IPO 68

Key Metrics for management s compensation Quantitative goals Perception Studies Revenue EBITDA (R$) Number of members Beneficiaries Dentists HR managers Quality of services 69

OdontoPrev awarded for the 8th consecutive year... Best Healthcare Sector IR Team of Latin America 2010 / 2011 / 2012 / 2013 / 2014 / 2015 / 2016 / 2017... Thank you! 70

Feedback from the street Well-run company, experienced and focused management team, complying with high Corporate Governance standards. Leadership position in a defensive market with favorable growth prospects. Strong balance sheet and cash generative business. One of the world s best emerging markets business models We continue to view OdontoPrev as the best business model in the healthcare segment, combining a high return and cash-flow-generation profile. #1 Company in Latin America with a technological competitive advantage Strong fundamentals stand out on current environment. We believe that high multiples are supported by: 1) strong FCF generation; 2) balance sheet with no debt; 3) dividend yield and 4) high earnings visibility. 71

Upcoming IR events Date Country Broker Event Oct 3, 2017 Oct 12, 2017 Oct 13, 2017 Oct 25, 2017 Oct 26, 2017 Oct 26, 2017 Nov 1, 2017 Nov 13, 2017 Nov 14-15, 2017 Nov 16-17, 2017 NDR Bradesco - Santiago NDR HSBC - Johannesburg NDR HSBC - Cape Town 3Q17 Earnings Release 3Q17 Webcast Investor Presentation - São Paulo NDR Credit Suisse - Rio de Janeiro ESG NDR UBS - New York Bradesco 7th Annual CEO Forum - New York ESG NDR HSBC - London Nov 20-21, 2017 Itaú BBA's 10th LatAm Conference - London Nov 30, 2017 JP Morgan 10th Brazil Opportunities Conference - São Paulo Jan 10-12, 2018 Jan 30-31, 2018 Morgan Stanley 10th Annual LatAm Executive Conference - Miami Credit Suisse LatAm Investment Conference - São Paulo 72 OdontoPrev s Investor Relations activities, including conference calls, webcasts, one-on-one meetings and public presentations are made by the Company s CEO and/or IRO since the 2006 IPO.

Why OdontoPrev? Largest and best network of dental specialists Proven & sustainable business model State-of-the-art IT platform Superior corporate governance standards Solid capital structure Proven management with an incentive to drive shareholder value Multiple growth drivers High returns on capital 73

Your award winning Investor Relations Team José Roberto Pacheco Executive Director & IRO Roberta Carneiro IR Manager Phone: + 55 (11) 4878-8893 E-mail: ir@odontoprev.com.br www.odontoprev.com.br/ir : OdontoPrevIR Darcio Nunciatelli IR Analyst Corporate Headquarters Avenida Marcos Penteado de Ulhôa Rodrigues 939 Torre II / Edifício Jatobá / 14 th floor Barueri. São Paulo. Brazil 06460-040 Stella Hong IR Analyst Custodian & Market Maker Independent Auditors B3 Ticker 74